Roche reports positive interim Phase 3 results for kidney drug, paving way for accelerated approval

Roche announced interim results from its Phase 3 trial of a kidney disease therapy, indicating the study met its primary endpoints.

The data, released on Wednesday, suggest the drug could qualify for accelerated approval, which would speed its entry into a market already populated by treatments from Novartis, Calliditas, Travere, Otsuka and Vera.

If the final trial confirms these findings, Roche would join a competitive landscape of kidney disease medicines, offering another option for patients and potentially expanding its portfolio in the therapeutic area.